• Tidak ada hasil yang ditemukan

https://links.lww.com/MLR/A914

N/A
N/A
Protected

Academic year: 2024

Membagikan "https://links.lww.com/MLR/A914"

Copied!
5
0
0

Teks penuh

(1)

Table S2. Distribution* of Measure Score (Use of the Measure among Eligible Cases Per Hospital).

Measure Name

N Mean SD 10% 25% 50% 75% 90%

Difference between

90th Percentile

and 10th Percentile AMI Patients Given

Aspirin at Arrival

2006 326682 96.50 4.37 93 96 98 99 100 7

2007 318714 97.02 4.18 94 96 98 99 100 6

2008 322853 97.61 3.85 95 97 99 99 100 5

2009 338530 98.26 3.24 96 98 99 100 100 4

2010 384424 98.76 2.76 97 98 99 100 100 3

2011 483776 99.22 1.60 98 99 100 100 100 2

AMI Patients Given Aspirin at

Discharge

2006 392736 96.52 5.54 92 96 98 99 100 8

2007 390164 96.98 4.97 93 97 98 99 100 7

2008 390615 97.34 4.65 94 97 99 99 100 6

2009 408993 98.29 3.72 96 98 99 100 100 4

2010 425585 98.70 3.33 97 99 99 100 100 3

2011 423225 99.10 2.24 98 99 100 100 100 2

AMI Patients Given ACEI or ARB for LVSD

2006 98864 86.52 10.58 74 81 88 94 98 24

2007 87887 90.02 9.61 79 86 92 97 100 21

2008 78855 93.44 8.11 85 91 96 99 100 15

2009 77570 95.33 6.81 89 93 97 100 100 11

2010 77258 96.33 6.28 91 95 98 100 100 9

2011 70917 97.47 4.06 93 96 99 100 100 7

AMI Patients Given Smoking Cessation Advice/Counseling

2006 141777 96.51 7.41 91 96 99 100 100 9

2007 139983 97.92 5.80 95 98 100 100 100 5

2008 138085 98.67 4.55 97 99 100 100 100 3

2009 138176 99.32 3.21 98 100 100 100 100 2

2010 138609 99.57 2.69 99 100 100 100 100 1

2011 135898 99.77 1.24 99 100 100 100 100 1

AMI Patients Given Beta Blocker at Discharge

2006 409922 96.08 5.54 91 95 98 99 100 9

2007 399837 96.86 4.86 93 96 98 99 100 7

2008 390267 97.46 4.47 94 97 99 100 100 6

2009 400637 98.15 3.73 96 98 99 100 100 4

2010 414736 98.43 3.51 96 98 99 100 100 4

2011 411512 98.94 2.38 97 99 100 100 100 3

(2)

Table S2. Distribution* of Measure Score (Use of the Measure among Eligible Cases Per Hospital) (continued).

AMI Patients Given PCI Within 90 Minutes Of Arrival

2006 25096 60.08 21.98 29 45 62 76 88 59

2007 51870 68.31 18.49 43 58 71 82 90 47

2008 53996 79.46 15.60 59 72 83 91 95 36

2009 55445 87.18 12.41 73 83 90 96 99 26

2010 58573 90.92 10.18 80 88 94 98 100 20

2011 59342 93.67 7.99 86 91 96 99 100 14

AMI Patients Composite Measure 2006

139507

7 95.02 4.46 90 94 96 98 99 9

2007 138845

5 95.54 4.02 92 94 96 98 99 7

2008

137467

1 96.64 3.66 93 96 98 99 99 6

2009 141935

1 97.75 2.99 95 97 98 99 100 5

2010

149918

5 98.29 2.69 97 98 99 100 100 3

2011 158467

0 98.88 1.77 98 99 99 100 100 2

Linear Trend over

time <.0001

0.000

4 0.0009

HF Patients Given Discharge

Instructions

2006 689463 69.11 20.52 42 57 73 85 93 51

2007 680447 74.45 18.83 49 65 78 89 95 46

2008 641658 80.77 16.13 60 73 84 93 98 38

2009 654792 86.62 13.14 70 82 90 96 99 29

2010 640279 89.99 10.93 77 86 93 97 100 23

2011 613810 92.36 9.22 83 89 95 98 100 17

HF Patients Given an Evaluation of LVS

2006 871642 92.36 10.11 84 90 95 98 99 15

2007 840732 93.88 9.24 86 93 97 99 100 14

2008 792237 95.70 7.98 90 95 98 99 100 10

2009 807513 97.41 6.86 95 98 99 100 100 5

2010 794594 98.13 6.09 96 99 100 100 100 4

2011 761944 98.78 5.04 98 99 100 100 100 2

HF Patients Given ACEI or ARB for LVSD

2006 322674 85.29 9.76 73 79 86 92 97 24

2007 294141 88.47 8.96 77 84 90 95 98 21

2008 260837 91.76 7.85 82 89 94 97 99 17

2009 264628 93.86 7.11 86 92 96 99 100 14

2010 254696 94.95 6.66 88 93 97 99 100 12

2011 231994 96.22 5.45 91 95 98 100 100 9

HF Patients Given

(3)

Smoking Cessation Advice/Counseling

2006 147594 91.23 13.80 76 89 96 100 100 24

2007 143742 94.20 11.47 84 94 98 100 100 16

2008 134385 96.65 8.80 91 97 100 100 100 9

Table S2. Distribution* of Measure Score (Use of the Measure among Eligible Cases Per Hospital) (continued).

2009 139286 98.09 6.67 96 99 100 100 100 4

2010 134626 98.65 6.05 98 100 100 100 100 2

2011 124852 99.35 3.00 98 100 100 100 100 2

HF Patients

Composite Measure

2006 203137

3 83.26 11.13 70 78 85 91 95 25

2007 195906

2 86.34 10.35 74 82 88 93 97 23

2008 182911

7 89.97 8.88 80 87 92 96 98 18

2009 186621

9 93.17 7.45 86 91 95 97 99 13

2010 182419

5 94.87 6.42 89 93 96 98 100 11

2011 173260

0 96.20 5.33 92 95 98 99 100 8

Linear Trend over

time 0.0002 0.000

5 0.0022

PN Patients Assessed and Given

Pneumococcal Vaccination

2006 497001 74.61 18.22 49 65 79 88 94 45

2007 545271 81.10 15.62 62 75 85 92 96 34

2008 539686 86.78 13.14 72 83 91 95 98 26

2009 506176 92.03 10.26 83 90 95 98 99 16

2010 517731 93.93 9.20 86 93 97 99 100 14

2011 532318 95.64 7.51 90 95 98 99 100 10

PN Patients Whose Initial ER Blood Culture Was Performed Prior To The Administration Of The First

Hospital Dose Of Antibiotics

2006 530118 90.12 6.32 82 87 91 95 97 15

2007 500207 90.52 6.37 82 88 92 95 97 15

2008 506490 92.43 6.25 85 90 94 97 98 13

2009 511417 94.79 5.26 89 93 96 98 99 10

2010 518579 96.15 4.55 92 95 97 99 100 8

2011 553652 96.91 3.92 93 96 98 99 100 7

PN Patients Given Smoking Cessation Advice/Counseling

2006 183193 88.18 14.75 70 83 93 98 100 30

(4)

2007 209876 91.67 12.69 77 90 96 99 100 23

2008 206637 94.34 10.52 84 94 98 100 100 16

2009 213060 96.88 7.70 92 97 100 100 100 8

2010 204316 97.73 6.72 94 98 100 100 100 6

2011 211107 98.51 4.83 96 99 100 100 100 4

PN Patients Given Initial Antibiotic(s) within 6 Hours After Arrival

2006 631131 79.32 10.27 66 74 81 87 91 25

2007 246898 93.27 6.61 86 91 95 97 99 13

Table S2. Distribution* of Measure Score (Use of the Measure among Eligible Cases Per Hospital) (continued).

2008 552525 93.36 6.06 87 92 95 97 98 11

2009 560508 94.58 5.54 90 93 96 98 99 9

2010 548022 95.61 4.69 91 94 97 98 99 8

2011 561182 96.10 4.42 92 95 97 99 100 8

PN Patients Given the Most

Appropriate Initial Antibiotic(s)

2006 437475 85.56 8.10 76 82 87 91 94 18

2007 394512 88.75 7.18 81 86 90 93 96 15

2008 373462 88.71 7.32 80 86 90 93 96 16

2009 369239 91.05 7.09 84 88 92 95 98 14

2010 347834 92.69 6.82 86 91 94 97 98 12

2011 353574 94.76 5.92 90 93 96 98 99 9

PN Patients Assessed and Given Influenza Vaccination

2006 111898 70.69 21.86 41 58 75 88 95 54

2007 207850 78.48 18.14 55 71 83 91 96 41

2008 408290 82.19 14.91 64 77 86 92 96 32

2009 182669 89.55 12.02 76 86 93 97 100 24

2010 185368 91.42 10.69 81 88 94 98 100 19

2011 183012 93.69 8.68 85 92 96 99 100 15

PN Patients

Composite Measure

2006 239081

6 82.15 8.37 71 78 83 88 91 20

2007 210461

4 86.99 8.17 77 84 89 92 95 18

2008 258709

0 89.45 7.39 81 87 91 94 96 15

2009 234306

9 93.34 5.74 88 92 95 97 98 10

2010 232185

0 94.77 5.20 90 94 96 98 99 9

2011 184119

3 95.75 4.89 92 95 97 98 99 7

Linear Trend over

time 0.0003 0.001

6 0.0048

(5)

* Number of Eligible Cases for The Measure Per Hospital

AMI: acute myocardial infarction, HF: heart failure, PN: pneumonia

Referensi

Dokumen terkait

Predictors of Stroke in High – Risk Patients After Acute Myocardial Infarction: Insights From The VALIANT Trial.. European

Berdasarkan uraian tersebut maka rumusan masalah dalam penelitian ini adalah “bagaimanakah gambaran profil lipid pada pasien acute myocardial infarction (AMI)

Introduction: Acute upper back pain as one of the atypical symptoms of acute myocardial infarction (AMI) is more frequently encountered in women, elderly, diabetics, and

Renal Failure and Acute Myocardial Infarction: Clinical Characteristics in Advanced Chronic Kidney Disease, Dialysis, and Non-Chronic Kidney Disease Patients.. A

The TOPCARE- AMI transplantation of progenitor cells and regeneration enhancement in acute myocardial infarction with 59 patients showed improvement in ejection fraction and infarct

Conditions Included in Centers for Disease Control and Prevention Severe Maternal Morbidity Composite Acute Myocardial infarction/aneurysm Acute renal failure Adult respiratory

Definition of complications MEDICAL Cardiovascular  Heart failure: clinical or radiological signs of congestive heart failure and specific treatment initiated.1  Acute myocardial

5 Model 2 additionally accounted for comorbidities dementia, myocardial infarction, congestive heart failure, peripheral vascular disease, connective tissue disease, lung disease,